What is the enterprise value (EV) for Processa Pharmaceuticals, Inc. (PCSA)?

The enterprise value (EV) for PCSA stock is $-1.44M.

Processa Pharmaceuticals (PCSA) Enterprise Value: History & Chart

Compare

Processa Pharmaceuticals, Inc.(PCSA)

Biotechnology · Vero Beach, FL

$1.48-0.01 (-0.67%)

Delayed quote: Oct 6, 2026, 12:50 PM EDT

Compare

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.

Vero Beach, FL

12 employees

www.processapharmaceuticals.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: George K. Ng

View full financials

NAME	MARKET CAP	ENTERPRISE VALUE (EV)
Processa Pharmaceuticals, Inc. (PCSA)	$4.10M	$-1.44M
GRI Bio, Inc. (GRI)vs ›	$4.15M	N/A
60 Degrees Pharmaceuticals, Inc. (SXTP)vs ›	$4.19M	$3.31M
Aptevo Therapeutics Inc. (APVO)vs ›	$4.00M	N/A
20/20 Biolabs Inc. (AIDX)vs ›	$4.21M	$237044.00
Ernexa Therapeutics Inc. (ERNA)vs ›	$3.85M	N/A
PharmaCyte Biotech, Inc. (PMCB)vs ›	$4.40M	N/A
CollPlant Biotechnologies Ltd. (CLGN)vs ›	$4.43M	$4.14M
Dermata Therapeutics, Inc. (DRMA)vs ›	$4.52M	$112147.00
Nexalin Technology, Inc. (NXL)vs ›	$3.58M	$2.58M

NAME

MARKET CAP

ENTERPRISE VALUE (EV)

Processa Pharmaceuticals, Inc. (PCSA)

$4.10M

$-1.44M

GRI Bio, Inc. (GRI)vs ›

$4.15M

N/A

60 Degrees Pharmaceuticals, Inc. (SXTP)vs ›

$4.19M

$3.31M